Clinical Trial Update: A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug [Phase 3]

View source ↗

Summary

A pediatric Phase 3 trial investigating long-term safety and tolerability of a drug for epilepsy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Epilepsy | Phase 3 | Status: WITHDRAWN